The report “OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017″ by GlobalData is now available at RnRMarketResearch.com. Contact sales@rnrmarketresearch.com with OpportunityAnalyzer: Endometriosis – Opportunity Analysis and Forecasts to 2017 in subject line and your contact details to purchase this report or get your questions answered. Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosis-associated pain can be so debilitating that it affects their ability to perform daily functions and significantly deters their quality of life. The KOL’s agree patients with endometriosis have significant unmet needs due to the lack of approved treatment options that have both continuous efficacy and a favorable long-term safety profiles. Although the KOLs are optimistic about the potential approval of GnRH antagonists, they still foresee that unmet needs will persist. Being orally active is a major benefit for GnRH antagonists. As such research foresees they will rapidly shift market share away from GnRH agonists. However their price will limit penetration in other patient segments. Ultimately, since none of the marketed, off-label, or pipeline drugs are curative, significant opportunity will remain for safe, efficacious therapies that target the root cause of the condition. In 2012, the global market was largely dominated by the US, with sales of $1.1bn. Combined sales in the 5EU were estimated to be $137.6m. By 2017, Research forecasts global endometriosis therapeutics sales to grow slowly to $1.2bn at a compound annual growth rate (CAGR) of 0.19%. Highlights Key Questions Answered The endometriosis therapeutics market has had weak competition due to a lack of approved therapies, and high rates of off-label drug use. What are the underlying unmet needs in this market? What opportunities will remain after elagolix is launched? The late-stage pipeline is comprised of GnRH antagonists. What sort of impact will these therapies have on this market? Which will emerge as market leaders? How will these products fare against existing therapies? Complete Report Available @ http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunity-analysis-and-forecasts-to-2017-market-report.html . The endometriosis therapeutics market has considerable unmet needs due to low diagnosis rates, minimal disease awareness, and lack of a well-tolerated long-term treatment options. Which drivers and barriers will affect the market landscape? What trends can be expected in each of US and 5EU?

1. OpportunityAnalyzer: Endometriosis – Opportunity Analysis and
Forecasts to 2017
by
GlobalData
Explore all reports for “ Women's Health Therapeutics ” market
@
http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals/therapeutics/womens-healththerapeutics .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

2. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory
condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause
chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosisassociated pain can be so debilitating that it affects their ability to perform daily functions and
significantly deters their quality of life.
The KOL’s agree patients with endometriosis have significant unmet needs due to the lack of
approved treatment options that have both continuous efficacy and a favorable long-term safety
profiles. Although the KOLs are optimistic about the potential approval of GnRH antagonists, they
still foresee that unmet needs will persist. Being orally active is a major benefit for GnRH
antagonists. As such research foresees they will rapidly shift market share away from GnRH agonists.
However their price will limit penetration in other patient segments. Ultimately, since none of the
marketed, off-label, or pipeline drugs are curative, significant opportunity will remain for safe,
efficacious therapies that target the root cause of the condition.
In 2012, the global market was largely dominated by the US, with sales of $1.1bn. Combined sales in
the 5EU were estimated to be $137.6m. By 2017, Research forecasts global endometriosis
therapeutics sales to grow slowly to $1.2bn at a compound annual growth rate (CAGR) of 0.19%.
Inquire for Discount @
http://www.rnrmarketresearch.com/contacts/discount?rname=146887 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

3. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
Highlights
Key Questions Answered
The endometriosis therapeutics market has had weak competition due to a lack of approved
therapies, and high rates of off-label drug use. What are the underlying unmet needs in this
market? What opportunities will remain after elagolix is launched?
The late-stage pipeline is comprised of GnRH antagonists. What sort of impact will these therapies
have on this market? Which will emerge as market leaders? How will these products fare against
existing therapies?
The endometriosis therapeutics market has considerable unmet needs due to low diagnosis rates,
minimal disease awareness, and lack of a well-tolerated long-term treatment options. Which
drivers and barriers will affect the market landscape? What trends can be expected in each of US
and 5EU?
Complete Report Available @
http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunityanalysis-and-forecasts-to-2017-market-report.html .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

4. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
Key Findings
•The single most important driver of growth will be the launch of novel agents with superior
safety and more convenient oral formulations
•GnRH agonists will rapidly shift market share from GnRH agonists however their price will limit
penetration in other patient share segments
•Incomplete knowledge regarding disease pathogenesis and pathophysiology creates a major
obstacle in the development of novel therapeutics
•Ultimately, since none of the marketed, off-label, and pipeline drugs are curative, significant
opportunity will remain for safe, efficacious therapies that target the root cause of the
condition.
Scope
•Overview of endometriosis, including epidemiology, etiology, pathophysiology, symptoms,
diagnosis, and treatment guidelines.
•Annualized endometriosis therapeutics market revenue, annual cost of therapy, and top line
US and 5EU market forecasts from 2012 to 2017.
Buy a copy of report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=146887 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

5. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
•Key topics covered include: strategic competitor assessment, market characterization, unmet
needs, and implications for the endometriosis therapeutics market.
•Pipeline analysis: comprehensive data split across different phases, emerging novel trends
under development, and detailed analysis of late-stage pipeline drugs.
•Analysis of the current and future market competition in the global endometriosis
therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
•Develop and design your in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most robust pipeline.
Additionally a list of acquisition targets included in the pipeline product company list.
•Develop business strategies by understanding the trends shaping and driving the global
endometriosis therapeutics market.
Buy a copy of report @
http://www.rnrmarketresearch.com/contacts/purchase?rname=146887 .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

6. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
•Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analysing the performance of various competitors.
•Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
•Drive revenues by understanding the key trends, innovative products and technologies, market
segments, and companies likely to impact the global endometriosis therapeutics market in
future.
•Track drug sales in the global endometriosis therapeutics market from 2012-2017.
•Organize your sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
partnerships.
Complete Report Available @
http://www.rnrmarketresearch.com/opportunityanalyzer-endometriosis-opportunityanalysis-and-forecasts-to-2017-market-report.html .
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

7. OpportunityAnalyzer: Endometriosis – Opportunity
Analysis and Forecasts to 2017
For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com /
+18883915441
RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.
© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441